Brian A. Lanman

4.1k citations

33 papers · 2.7k · 1 hit paper · h-index 18

Impact in

Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Organic Chemistry top 5%
- Synthesis and biological activity

Papers in

Organic Chemistry 14
- Synthesis and biological activity 4
- Asymmetric Synthesis and Catalysis 3
- Advanced Synthetic Organic Chemistry 3
Molecular Biology 19
- Sphingolipid Metabolism and Signaling 7
- Protein Kinase Regulation and GTPase Signaling 5
- PI3K/AKT/mTOR signaling in cancer 3
- Melanoma and MAPK Pathways 3

Co-authors: Andrew G. Myers (4 shared papers)Larry E. Overman (2 shared papers)Andrew T. Parsons (1 shared paper)Stephan G. Zech (1 shared paper)Boyu Zhong (2 shared papers)Mohammad Movassaghi (2 shared papers)Daniel W. Kung (2 shared papers)Ralph Paulini (1 shared paper)
Journals: Bioorganic & Medicinal Chemistry Letters (8 papers)Journal of Medicinal Chemistry (6 papers)ACS Medicinal Chemistry Letters (6 papers)Journal of the American Chemical Society (2 papers)Organic Letters (2 papers)
Partner nations: United States

In The Last Decade

Brian A. Lanman

32 papers receiving 2.6k citations

Brian A. Lanman's Hit Papers

align trajectories log scale

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity 2019 · 1.8k citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2019 Nature

Peers

Countries citing papers authored by Brian A. Lanman

Since Specialization

Citations

This map shows the geographic impact of Brian A. Lanman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian A. Lanman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian A. Lanman more than expected).

Fields of papers citing papers by Brian A. Lanman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian A. Lanman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian A. Lanman. The network helps show where Brian A. Lanman may publish in the future.

Co-authors

The 25 scholars most cited alongside Brian A. Lanman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brian A. Lanman Line = papers co-authored together Brian A. Lanman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity Nature ·Jude R. Canon, Karen L. Rex, Anne Y. Saiki, Keegan S. Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G. Knutson Hit paper breakdown →	2019	1759
2	Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C ACS Medicinal Chemistry Letters ·Youngsook Shin, Joon Won Jeong, Ryan P. Wurz, Pragathi Achanta, Tara Arvedson, Michael D. Bartberger, Iain D. G. Campuzano, Raymond V. Fucini	2019	93
3	Synthesis of highly epimerizable N-protected α-amino aldehydes of high enantiomeric excess Tetrahedron Letters ·Andrew G. Myers, Boyu Zhong, Mohammad Movassaghi, Daniel W. Kung, Brian A. Lanman +1 other	2000	88
4	Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations Accounts of Chemical Research ·Brian A. Lanman, Andrew T. Parsons, Stephan G. Zech	2022	74
5	On the Structure of Palau'amine: Evidence for the Revised Relative Configuration from Chemical Synthesis Journal of the American Chemical Society ·Brian A. Lanman, Larry E. Overman, Ralph Paulini, Nicole S. White	2007	69
6	Efficient, Stereoselective Synthesis of trans-2,5-Disubstituted Morpholines Organic Letters ·Brian A. Lanman, Andrew G. Myers	2004	63
7	A Solid-Supported, Enantioselective Synthesis Suitable for the Rapid Preparation of Large Numbers of Diverse Structural Analogues of (−)-Saframycin A Journal of the American Chemical Society ·Andrew G. Myers, Brian A. Lanman	2002	53
8	Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5 ACS Medicinal Chemistry Letters ·Victor J. Cee, Mike Frohn, Brian A. Lanman, Jennifer E. Golden, Kristine M. Muller, Susana Neira, Alex Pickrell, Heather A. Arnett	2010	49
9	Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases Journal of Medicinal Chemistry ·Adrian Lloyd Smith, Noel D. D’Angelo, Yunxin Y. Bo, Shon K. Booker, Victor J. Cee, Brad Herberich, Fang‐Tsao Hong, Claire L. M. Jackson	2012	46
10	Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511 Journal of Medicinal Chemistry ·Mark H. Norman, Kristin L. Andrews, Yunxin Y. Bo, Shon K. Booker, Sean R. Caenepeel, Victor J. Cee, Noel D. D’Angelo, Daniel J. Freeman	2012	46
11	Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors Journal of Medicinal Chemistry ·Liping H. Pettus, Kristin L. Andrews, Shon K. Booker, Jie Chen, Victor J. Cee, Frank Chavez, Yuping Chen, Heather A. Eastwood	2016	38
12	The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Huiling Wang, Victor J. Cee, Frank Chavez, Brian A. Lanman, Anthony B. Reed, Bin Wu, Nadia T. Guerrero, James Russell Lipford	2014	32
13	Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors Bioorganic & Medicinal Chemistry Letters ·Bin Wu, Huiling Wang, Victor J. Cee, Brian A. Lanman, Thomas E. Nixey, Liping H. Pettus, Anthony B. Reed, Ryan P. Wurz	2015	29
14	Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors ACS Medicinal Chemistry Letters ·Victor J. Cee, Frank Chavez, Bradley J. Herberich, Brian A. Lanman, Liping H. Pettus, Anthony B. Reed, Bin Wu, Ryan P. Wurz	2016	26
15	The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Ryan P. Wurz, Liping H. Pettus, Claire L. M. Jackson, Bin Wu, Huiling Wang, Brad Herberich, Victor J. Cee, Brian A. Lanman	2015	25
16	Synthesis of C-Protected α-Amino Aldehydes of High Enantiomeric Excess from Highly Epimerizable N-Protected α-Amino Aldehydes Organic Letters ·Andrew G. Myers, Boyu Zhong, Daniel W. Kung, Mohammad Movassaghi, Brian A. Lanman +1 other	2000	24
17	Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies Journal of Medicinal Chemistry ·Hui-Ling Wang, Kristin L. Andrews, Shon K. Booker, Jude R. Canon, Victor J. Cee, Frank Chavez, Yuping Chen, Heather A. Eastwood	2019	24
18	Evaluation of Strategies for the Synthesis of the Guanidine Hemiaminal Portion of Palau’amine Heterocycles ·Larry E. Overman, Brian A. Lanman	2006	22
19	Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1) ACS Medicinal Chemistry Letters ·Brian A. Lanman, Victor J. Cee, Srinivasa R. Cheruku, Mike Frohn, Jennifer E. Golden, Jian Lin, Mercedes Lobera, Yael Marantz	2010	18
20	Quinolinone-based agonists of S1P1: Use of a N-scan SAR strategy to optimize in vitro and in vivo activity Bioorganic & Medicinal Chemistry Letters ·Lewis D. Pennington, Michael D. Croghan, Kelvin K. C. Sham, Alexander J. Pickrell, Paul E. Harrington, Michael J. Frohn, Brian A. Lanman, Anthony B. Reed	2011	17

About Brian A. Lanman

Brian A. Lanman is a scholar working on Organic Chemistry, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Pharmacology, having authored 33 papers that have together received 2.7k indexed citations. Recurring topics across this work include Sphingolipid Metabolism and Signaling (7 papers), Protein Kinase Regulation and GTPase Signaling (5 papers), Lung Cancer Treatments and Mutations (4 papers), Synthesis and biological activity (4 papers), Asymmetric Synthesis and Catalysis (3 papers), Advanced Synthetic Organic Chemistry (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Melanoma and MAPK Pathways (3 papers). The work is most often cited by research in Oncology (527 citations), Organic Chemistry (665 citations), Molecular Biology (1.2k citations), Cancer Research (205 citations) and Pulmonary and Respiratory Medicine (431 citations). Brian A. Lanman has collaborated with scholars based in United States. Frequent co-authors include Andrew G. Myers, Larry E. Overman, Andrew T. Parsons, Stephan G. Zech, Boyu Zhong, Mohammad Movassaghi, Daniel W. Kung, Ralph Paulini, Victor J. Cee and Anthony B. Reed. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, Journal of the American Chemical Society and Organic Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Brian A. Lanman

Impact in

Papers in i

In The Last Decade

Brian A. Lanman

Brian A. Lanman's Hit Papers

Peers

Countries citing papers authored by Brian A. Lanman

Fields of papers citing papers by Brian A. Lanman

All Works

About Brian A. Lanman

Explore authors with similar magnitude of impact

Papers in